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Diabetic cardiomyopathy (DCM) is a relatively prevalent disease associated with high morbidity 10 
and mortality rates. 11 
 12 
The current criteria to diagnose DCM include left ventricular (LV) diastolic dysfunction, reduced 13 
LV ejection fraction, pathological LV hypertrophy and interstitial fibrosis. However, it is difficult 14 
to identify DCM in the early stages because of its heterogeneity. 15 
 16 
There are some validated biomarkers for the diagnosis and risk assessment of numerous cardiac 17 
diseases, but none of them is able to discriminate those patients with DCM. 18 
 19 
The diabetic heart is characterized by metabolic disturbances that are often accompanied by local 20 
inflammation, oxidative stress, myocardial fibrosis and cardiomyocyte apoptosis. The discovery 21 
of selected biomarkers that integrate these processes is of great interest to detect or prevent DCM 22 
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The diabetic heart is characterized by metabolic disturbances that are often accompanied by local 27 
inflammation, oxidative stress, myocardial fibrosis and cardiomyocyte apoptosis. Overall changes 28 
result in contractile dysfunction, concentric left ventricular hypertrophy and dilated 29 
cardiomyopathy, altogether affecting cardiac output and eventually leading to heart failure, the 30 
foremost cause of death in diabetic patients. There are currently a number of validated biomarkers 31 
for the diagnosis and risk assessment of several cardiac diseases, but none of them is capable of 32 
discriminating patients with diabetic cardiomyopathy. In this review we point to several novel 33 
candidate biomarkers from new activated molecular pathways (including microRNAs) with the 34 
potential to detect or prevent diabetic cardiomyopathy in the early stages, or even to treat it once 35 
established. The prospective use of selected biomarkers that integrate inflammation, oxidative 36 
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Diabetic cardiomyopathy: where we are 76 
Diabetic cardiomyopathy (DCM) is currently defined as myocardial dysfunction that develops in 77 
diabetic patients, and which is not directly attributable to hypertension, valve disease or coronary 78 
artery disease. Its prevalence ranges from 20% to 60% in the diabetic population[1, 2], and affects 79 
both people with type 1 (DM1) and type 2 (DM2) diabetes[3]. The diabetic heart is characterized 80 
by metabolic disturbances, which, together with subcellular component abnormalities and 81 
immunological alterations, locally prompt inflammation, oxidative stress, mitochondrial 82 
dysfunction and apoptosis (see Glossary). Overall changes result in extracellular cardiac 83 
remodeling and fibrosis, contractile dysfunction, concentric left ventricular hypertrophy and 84 
dilated cardiomyopathy, which affect cardiac output and eventually lead to heart failure, the 85 
foremost cause of death in diabetic patients[4]. 86 
Current criteria to diagnose DCM (Box 1) include left ventricular diastolic dysfunction, reduced 87 
left ventricular ejection fraction (LVEF), pathological cardiac hypertrophy and interstitial 88 
fibrosis[5]. However, it is often difficult to identify DCM in the early stages because of its 89 
heterogeneity. For this reason, it is essential that early molecular events are identified that would 90 
allow early diagnosis. This would enable a reliable assessment of the disease, and would boost the 91 
use of novel therapeutic strategies to delay or prevent its progression to heart failure. Nowadays, 92 
there is an increased trend towards the identification of new activated molecular pathways and 93 
mediators involved in the pathogenesis of DCM. Quantification of molecular biomarkers could 94 
provide an interesting tool to both improve DCM detection, and to discover new therapeutic targets 95 
(Box 2). In spite of the considerable panel of candidates, however, no molecule has proven to be 96 
useful in clinical practice to date. Thus, the identification of potential cardiac biomarkers that are 97 
released during early and reversible alterations is of great interest. Numerous molecules with 98 
autocrine and paracrine effects are excreted by the heart in response to the structural and functional 99 
alterations associated with diabetes. These molecules are involved in processes as diverse as 100 
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inflammation, metabolism, contractility, fibrosis, hypertrophy and apoptosis. Interestingly, 101 
increasing evidence points to a potential link between chronic low-grade inflammation, fibrosis 102 
and metabolic dysregulation in heart diseases[4]. For that reason, we focus on those molecules of 103 
cardiac origin that could mediate the crosstalk between inflammation, cardiac remodelling and 104 
metabolic dysregulation in the failing heart during diabetes. 105 
 106 
Molecular basis of diabetic cardiomyopathy 107 
Metabolic remodeling plays a key role in diabetic cardiomyopathy 108 
The pathophysiological mechanisms of DCM are multifactorial (Figure 1), although it is widely 109 
accepted that metabolic dysregulation plays a pivotal role in its development. Free fatty acids 110 
(FFA) are the preferred energy substrate in the adult heart, although other substrates such as 111 
glucose, lactate or ketone bodies may provide additional fuel sources. At the transcriptional level, 112 
cardiac metabolism is mostly regulated by the PPAR (peroxisome proliferator-activated 113 
receptor)/PGC-1 (PPAR coactivator-1) axis, which along with its transcriptional targets, plays 114 
a central role in DCM[6]. One of these target genes, pyruvate dehydrogenase kinase 4 (PDK4), 115 
which catalyzes the rate-limiting step of glucose oxidation, is chronically elevated in the diabetic 116 
heart[7]. In contrast, the uptake of FA and glucose in the heart is mediated, respectively, by fatty 117 
acid translocase (FAT/CD36) and the insulin-induced glucose transporter 4 (GLUT4), which are 118 
both transcriptionally regulated by PPAR/PGC-1. Under insulin resistance, GLUT4 is 119 
internalized while FAT/CD36 becomes preferentially localized to the sarcolemma, thus promoting 120 
a substrate shift toward increased mitochondrial FA β-oxidation as the sole fuel source[8-10]. 121 
Despite the higher FA oxidation rate, myocardial lipid accumulation is a hallmark of the diabetic 122 
heart, and cardiac steatosis is currently regarded as a major cause of DCM[4, 11]. The ensuing 123 
accumulation of toxic lipid intermediates (lipotoxicity) is characterized by the activation of the 124 
proinflammatory transcription factor nuclear factor-B (NF-B), and the appearance of 125 
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endoplasmic reticulum (ER) stress and mitochondrial dysfunction, all linked to myocyte 126 
apoptosis, myocardial fibrosis and contractile dysfunction[3, 12].  127 
 128 
The role of inflammation and fibrosis 129 
Elevated FFA plasma levels and hyperglycemia activate NF-κB in cardiomyocytes[4]. The 130 
resultant increased expression and secretion of cytokines and chemokines exerts several autocrine 131 
effects via downstream activation of activator protein-1 (AP-1) and NF-B itself, which are 132 
actively involved in the development of heart failure during DCM[4, 13]. 133 
Hyperglycemia also induces the formation of advanced glycation end-products (AGE) within 134 
the cardiomyocytes[14], which, through the interaction with their receptor (RAGE, receptor for 135 
AGE), trigger NF-κB activation, hence modifying the overall gene expression in cardiomyocytes 136 
and reducing cardiac contractility[13]. Hyperglycemia-derived AGE induce the formation of 137 
structural proteins, type I and III collagens, promote the covalent crosslinking between various 138 
extra- and intracellular proteins, and elicit a switch in the expression from the  myosin heavy 139 
chain (MHC) isoform to the -MHC isoform[3, 15]. These changes favor interstitial fibrosis, 140 
myocardial stiffness and subsequent left ventricular diastolic dysfunction. 141 
 142 
Oxidative stress and apoptosis 143 
Hyperglycemia and undue FA oxidation in mitochondria during DCM promote reactive oxygen 144 
species (ROS) accumulation in cardiomyocytes, which lead to oxidative stress and are involved 145 
in all stages of DCM, including cardiac hypertrophy, fibrosis, contractile dysfunction and heart 146 
failure[15]. An excess of ROS brings on the uncoupling of oxidative metabolism, induces DNA, 147 
protein and lipid oxidative damage, triggers NF-κB activation, and gives rise to endoplasmic 148 
reticulum (ER) stress[3]. As a result, myocardial energy generation is impaired, calcium handling 149 
disturbed, and cardiac contractility and efficiency are reduced[3, 12]. In murine cardiomyocytes, 150 
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oxidative stress directly induces insulin resistance via up-regulation of the extracellular signal-151 
regulated protein kinase (ERK)1/2 activity, which inhibits the NF-E2-related factor 2 (Nrf2), a 152 
transcription factor that protects against sustained oxidative stress[16]. 153 
ROS accumulation also hastens cardiomyocyte apoptosis, which is often observed in the 154 
myocardium of animal models and patients with diabetes[15]. Apoptosis is caused by several 155 
mechanisms, including the activation of DNA reparative enzymes such as poly ADP ribose 156 
polymerase (PARP), or through interference with nitric oxide[15]. PARP also activates NF-B 157 
and diverts glucose metabolism from its usual glycolytic pathway, thus favoring hyperglycemia-158 
induced cell injury. The ensuing accumulation of glycolytic intermediates will, in turn, harm 159 
cardiac tissue via AGE formation and protein kinase C activation[15, 17].  160 
 161 
Other pathophysiological mechanisms 162 
ER stress is partly responsible for cardiomyocyte cell death in the heart of diabetic rats[18]. When 163 
ER stress is limited, activation of the unfolded protein response potentiates autophagy as a short-164 
term strategy to protect cardiac cells during diabetes[19]. In contrast, persistent ER stress will 165 
activate NF-κB, p38 MAPK (mitogen-activated protein kinase) and JNK (c-Jun N-terminal kinase) 166 
pathways, which in turn are responsible for the induction of ER stress-mediated cardiomyocyte 167 
apoptosis[20]. ER stress also alters cardiomyocyte calcium uptake and handling, thus aggravating 168 
diastolic relaxation dysfunction[3]. In fact, calcium ions are pivotal regulators of the process of 169 
excitation–contraction coupling in the heart (Box 3), and dysfunctional intracellular calcium 170 
signaling and transport have been observed in various murine models of diabetes[21-23], and also 171 
in diabetic patients with diastolic dysfunction[24]. 172 
 173 
Where are we going: Emerging actors in DCM 174 
Metabolism-related molecular biomarkers 175 
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The metabolic inflexibility that distinguishes the diabetic myocardium is characterized by 176 
increased  rates  of  fatty  acid  uptake  and  mitochondrial  oxidation  as  the  predominant  energy  177 
source. This affects the cardiac muscle by diverse mechanisms and acting on different 178 
cardiomyocyte compartments[25]. The inability of the diabetic heart to switch between substrates 179 
in the presence of different stressors may offer novel biomarkers representing the “struggle” of the 180 
heart to deal with these conditions. For instance, the phosphocreatine (PCr)/ATP ratio (Figure 2) 181 
is significantly reduced in the diabetic heart. Magnetic resonance spectroscopic imaging is suitable 182 
for the determination of phosphocreatine, ATP and triglyceride accumulation in the 183 
myocardium[3]. A recent study demonstrates that the PCr/ATP ratio predicts diastolic dysfunction 184 
in obese patients without cardiovascular risk factors[26]. However it is not able to discriminate 185 
those patients with DCM from other pathologies[3]. For instance, the PCr/ATP ratio is also 186 
reduced in patients with hypertensive heart disease without diabetes or overt systolic 187 
dysfunction[27]. 188 
The striated muscle-specific E3 ligase TRIM72 (tripartite motif containing 72, or mitsugumin 53, 189 
MG53) is another potential therapeutic target because it induces systemic insulin resistance, 190 
dyslipidemia and hyperglycemia. Its expression is also increased in the myocardium during 191 
diabetes[28]. Cardiac-specific overexpression of TRIM72 in mice results in insulin resistance, 192 
because it drives ubiquitin-dependent degradation of the insulin receptor and insulin receptor 193 
substrate 1[28]. This is followed by steatosis and, finally, severe DCM characterized by 194 
myocardial hypertrophy, fibrosis and cardiac dysfunction. Further metabolic effects of TRIM72 195 
arise from the transcriptional upregulation of PPAR-target genes involved in FA uptake and 196 
metabolism, together with the PDK-mediated repression of glycolysis[28]. Remarkably, PDKs 197 
and, in particular PDK4, have emerged as interesting candidates for diabetes therapy as they might 198 
link inflammation, apoptosis and insulin resistance[29, 30]. TRIM72 also plays an important role 199 
in cardiac fibrosis, probably through the modulation of transforming growth factor (TGF)[31]. 200 
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Conversely, several evidences have identified TRIM72 as an important cardioprotective factor. 201 
Cardiac ischemia/reperfusion insults downregulate myocardial TRIM72 protein levels, whereas 202 
elevation of TRIM72 protects cardiomyocytes from oxidative injury and alleviates cardiac 203 
ischemia/reperfusion injury[32]. Overall data suggest that, in acute myocardial infarction and 204 
cardiac ischemia/reperfusion injury, a transient and short-term increase of TRIM72 could protect 205 
against acute damage, whereas specific inhibition of its E3 ligase activity might prevent insulin 206 
resistance and lipid dysregulation in the heart. 207 
Similarly, TP53INP2 (tumor protein p53 inducible nuclear protein 2), the expression of which is 208 
induced by PPAR, regulates the expression of important glycolytic enzymes involved in glucose 209 
uptake and glycogen storage in cardiomyocytes[33]. Its protein levels are reduced in muscle from 210 
streptozotocin-induced diabetic mice and in obese diabetic db/db mice[28] and in muscle from 211 
DM2 patients[34]. TP53INP2 is a bifunctional protein that acts as a nuclear coactivator and key 212 
regulator of basal autophagy and protein degradation; as a consequence, it hinders the expression 213 
of hypertrophic genes, particularly in the context of hyperglycemia[33, 34]. Therefore, its 214 
activation in the heart might be therapeutically useful to delay cardiac hypertrophy and to prevent 215 
the metabolic dysregulation characteristic of DCM. 216 
Since cardiac steatosis is a hallmark of DCM, the identification of factors released during this 217 
process could be useful to detect or prevent the disease. The fatty acid binding protein 3 (FABP3), 218 
a cardiac-specific PPAR-induced protein that transports FA from the plasma membrane to the 219 
mitochondria for their subsequent oxidation after conjugation with carnitine by CPT-1 (carnitine 220 
palmitoyl-transferase 1), is released to the plasma after the onset of cell damage in patients with 221 
systolic dysfunction or heart failure[35]. FABP3 is detected in the serum of DM2 patients with 222 
early cardiac injury[36] and is correlated with cardiac insulin resistance in mice[37]. FABP3 is 223 
also increased in patients with hypertrophic and dilated cardiomyopathy, or heart failure[36]. In 224 
contrast, patients with reduced LVEF due to doxorubicin-induced cardiotoxicity display lower 225 
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plasma levels of FABP3[38]. FABP3 also protects against oxidative stress and mitochondrial 226 
dysfunction, and exerts an antiapoptotic role in cardiac cells[39]. Overall data suggest that FABP3 227 
could be a suitable diagnostic tool, but also a promising therapeutic target for treating DCM.  228 
Some autocrine and paracrine molecules secreted by the heart or the epicardial adipose tissue could 229 
also be useful as metabolic-related DCM biomarkers. Activin A is released in DM2 patients and 230 
is capable of inhibiting insulin secretion[40]. Moreover, plasma activin A levels are inversely 231 
correlated with myocardial glucose metabolism[41]. The activin A-mediated blockade of insulin-232 
mediated phosphorylation of phosphoinositide 3-kinase (PI3K)/Akt[40], a key regulator of 233 
myocardial glucose uptake, could account for these metabolic changes, and could reflect early 234 
DCM development. An even more promising biomarker is insulin-like growth factor binding 235 
protein-7 (IGFBP-7), a modulator of insulin receptor activity and signaling that displays a positive 236 
correlation with increased collagen deposition, fibrosis and cardiac hypertrophy in diabetes[37, 237 
42]. In fact, serum IGFBP-7 and TGF levels are elevated in diabetic patients, particularly in those 238 
displaying diastolic dysfunction[42]. In support of this, IGFBP-7 has been identified as a 239 
biomarker associated with cardiac hypertrophy and heart failure through systematic proteomic 240 
studies[43] and in patients with diastolic dysfunction and heart failure[44]. Of note, IGFBP-7 241 
displayed a similar performance and discrimination capacity than the natriuretic peptide B. 242 
 243 
Molecular biomarkers involved in inflammation and fibrosis  244 
Several proinflammatory cytokines (interleukins [IL]1 and IL6; monocyte chemoattractant protein 245 
1, MCP1; and tumor necrosis factor-, TNF-) involved in the progression of heart failure are 246 
secreted by both cardiomyocytes and cardiac fibroblasts of diabetic patients, particularly in those 247 
with diastolic dysfunction[15, 42]. These classical inflammatory biomarkers exert various 248 
autocrine and paracrine effects, including insulin resistance, mitochondrial injury, oxidative stress, 249 
fibrosis and apoptosis (Figure 3)[42]. Proinflammatory cytokines have previously been designated 250 
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as potential biomarkers in the early detection of DCM, although their plasma levels do not 251 
discriminate between DCM and other cardiac pathologies nor are they useful for stratifying 252 
patients according to their risk[45]. Furthermore, therapies aimed at inhibiting these cytokines 253 
(TNF-, IL1) have failed to ameliorate inflammation-induced insulin resistance and DCM in 254 
clinical studies[46]. 255 
Cardiotrophin-1 (CT-1), which belongs to the IL6 family of cytokines, is released by cardiac 256 
fibroblasts and cardiomyocytes in response to mechanical, metabolic and hypoxic stress[47]. 257 
Through the activation of gp130, CT-1 promotes cell survival by PI3K/Akt phosphorylation-258 
induced inactivation of the proapoptotic Bcl-2-associated death promoter (BAD) protein[47]. If 259 
the stressor persists, CT-1 promotes deleterious cardiac fibrosis and remodeling, cardiac 260 
hypertrophy and dysfunction and, eventually, heart failure[47]. CT-1 promotes cardiomyocyte 261 
hypertrophy through the JAK/STAT3 (janus kinase/signal transducer and activator of transcription 262 
3) and ERK5 pathways, whereas by activating p42/44 MAPK and PI3K/Akt it promotes 263 
cardiomyocyte survival[48]. CT-1 has also been proposed to activate NF-B and to induce insulin-264 
stimulated glucose uptake by cardiac cells, thus playing a crucial role in regulating glucose 265 
metabolism[37]. Plasma CT-1 levels are increased in patients with DM2 or impaired glucose 266 
tolerance, and these levels positively correlate with glycemia and left ventricular hypertrophy[49, 267 
50]. However, its high expression in other tissues besides the heart, and its increased expression 268 
in other non-diabetic cardiomyopathies hinder its usefulness as a biomarker in DCM [47]. 269 
Soluble ST2 (suppression of tumorigenicity 2) is a cardiac biomarker cleared by the Food and 270 
Drug Administration (FDA) to aid in assessing the prognosis of patients diagnosed with chronic 271 
heart failure[47]. ST2 is regarded as a decoy receptor of IL33, thus preventing the protective 272 
effects of this cytokine in obesity and cardiac remodeling[51]. Interestingly, DM2 patients exhibit 273 
higher plasma levels of soluble ST2, especially those people presenting diastolic dysfunction and 274 
inappropriate glycemic control[52]. However, it remains to be elucidated whether this is a 275 
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consequence rather than a cause of the inflammatory activation observed in the heart. In support 276 
of ST2 as a suitable biomarker for DCM, plasma levels of this receptor were independently 277 
associated with cardiovascular mortality in patients with heart failure and diabetes and the 278 
combination of ST2 with troponin T significantly increased its discrimination potential[53]. These 279 
biomarkers could be useful to predict the clinical course of heart failure in both the general 280 
population and in diabetic patients. 281 
Chitinase-3-like protein 1 (CHI3L1 or YKL-40) is a glycoprotein whose plasma levels are elevated 282 
in patients with diabetes or obesity and in people suffering myocardial infarction, coronary artery 283 
disease or ischemic heart disease[54]. Its plasma levels positively correlate with insulin resistance 284 
and the lipid profile (free FFA and triglycerides) in DM2 patients[55]. YKL-40 is involved in cell 285 
proliferation and differentiation, and could potentially protect the heart by attenuating 286 
inflammation, apoptosis, tissue remodeling and fibrosis[54, 56]. YKL-40 inhibits p38 and JNK 287 
MAPKs, a fact that counteracts the inflammatory responses induced by TNF- and IL1, and 288 
reduces the expression of matrix metalloproteinases (MMP)[55]. Secretion of YKL-40 is regulated 289 
by NF-B[56] and Sp1 (specificity protein 1)[57]. The latter is a transcription factor that, together 290 
with PPAR and NR2F2 (nuclear receptor subfamily 2 group F member 2) is responsible for 291 
decreasing FA utilization in the hypertrophied heart[58]. Thus, YKL-40 has the potential to 292 
become a biomarker for DCM, but also to prevent or even to treat it once established. However, 293 
the fact that insulin treatment does not correct YKL-40 serum levels in persons with type 2 diabetes 294 
mellitus[59] casts a doubt on its feasibility as a suitable biomarker for DCM. 295 
Another interesting mediator of the inflammatory response is HMGB1 (high-mobility group box 296 
1), the expression of which is increased in the heart during diabetes[60]. During DCM, HMGB1 297 
translocates from the nucleus to the cytoplasm and even to the myocardial interstitium, where it 298 
boosts fibrosis and inflammation[60]. These effects rely on the activation of MAPK and NF-B 299 
pathways, and subsequent stimulation of collagen deposition, increases in MMP2 and MMP9 300 
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activity, and production of TNF- and IL6[60, 61]. Inhibition of HMGB1 decreases myocardial 301 
inflammation and fibrosis in diabetic mice, thus ameliorating left ventricular dysfunction and 302 
cardiac remodeling[60]. It also protects the heart against hyperglycemia-induced apoptosis by 303 
downregulating ERK1/2 and caspase-3 activities[62], thus pointing to HMGB1 inhibition as a 304 
novel therapeutic target in the treatment of DCM, even once established[63]. In this regard, 305 
downregulation of HMGB1 has been reported to attenuate diabetes-induced cardiac dysfunction 306 
by the inhibition of inflammation, oxidative stress, fibrosis and apoptosis[63, 64]. 307 
During DCM the deposition of extracellular matrix protein impairs contractility and ultimately 308 
leads to cardiac stiffness and progression towards heart failure. Therefore, extracellular matrix 309 
synthesis and turnover could be a useful biomarker for the recognition, diagnosis and even 310 
prevention of fibrosis in DCM. In this regard, plasma levels of procollagen type-1 propeptide and 311 
MMP7 are positively correlated with diastolic dysfunction in diabetic patients, while MMP2 levels 312 
are reduced in experimental models of DM1 and DM2 displaying cardiac fibrosis and diastolic 313 
dysfunction [37]. MMP9 levels are increased in myocardial fibrosis and heart failure, and, 314 
interestingly, pharmacological or genetic inhibition of MMPs ameliorates cardiac remodeling in 315 
mice[65]. Likewise, procollagen type III aminopeptide in serum is an indicator of extracellular 316 
matrix turnover that has been proposed as a marker of early left ventricular dysfunction in subjects 317 
with insulin resistance[66].  318 
The proinflammatory transcription factors NF-B and AP-1 contribute in the course of DCM to 319 
the overexpression of collagens, fibronectin and TGFβ, in this way enhancing extracellular matrix 320 
protein accumulation[13]. Cardiac and plasma TGFβ levels are correlated with the degree of 321 
fibrosis in DCM, particularly in those subjects presenting concomitant diastolic dysfunction, and, 322 
notably, inhibition of TGFβ in animal models of DM2 prevents diastolic dysfunction[37, 42]. AP-323 
1, which is mostly composed of JUN and FOS heterodimers, regulates extracellular matrix 324 
deposition and decreases contractility and cell permeability, inducing cardiomyocyte hypertrophy 325 
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and fibrosis[67]. It is worth mentioning that downregulation of FOS transcription by miR-146a 326 
has the capacity to inhibit MMP9 activity[68], thus suggesting that this microRNA (miRNA) 327 
could be a promising therapeutic tool for preventing cardiac disorders associated with enhanced 328 
inflammation and fibrosis in the heart. Furthermore, miR-146a might prevent myocardial lipid 329 
accumulation and subsequent lipotoxic cardiomyopathy, because FOS is also an activator of lipid 330 
biosynthesis via a transcriptional-independent mechanism[69]. 331 
Growth differentiation factor 15 (GDF15), which belongs to the TGFβ superfamily and is highly 332 
expressed in the heart, suppresses the synthesis and secretion of proinflammatory cytokines (TNF-333 
 and IL6) and modulates cell growth and differentiation[70]. Its plasma levels are increased in 334 
diabetic patients, and positively correlate with obesity, fasting glucose levels, insulin resistance, 335 
plasma triglycerides and the proinflammatory marker C-reactive protein (CRP)[45], thus 336 
representing another potential biomarker. However, its usefulness in predicting disease 337 
progression, prognosis or protection of the heart is hindered by the fact that GDF15 is non-specific 338 
for metabolic diseases and also due to it is associated with increased cancer incidence in patients 339 
with type 2 diabetes[70]. 340 
Finally, galectin-3 (or Mac-2) is a beta-galactoside-binding lectin that is regarded as one of the 341 
key links between fibrosis, inflammation and adverse cardiac remodeling in heart failure[71]. In 342 
rodent models of heart failure, galectin-3 is locally secreted by activated macrophages and 343 
fibroblasts, where it exerts its profibrotic action by enhancing myofibroblast proliferation, 344 
accumulation of extracellular matrix, macrophage infiltration and cardiac hypertrophy, via 345 
stimulation of the TGFβ signaling pathway[71, 72]. Measurement of galectin-3 plasma levels has 346 
been proposed as a good predictor and prognostic biomarker of left ventricular systolic dysfunction 347 
and heart failure in diabetic subjects[73]. Galectin-3 might also be of therapeutic interest in DCM, 348 
since its inhibition prevents the increase of profibrotic and proinflammatory markers in some 349 
organs[74]. Similarly, its administration to mice causes insulin resistance and glucose intolerance, 350 
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whereas its pharmacological or genetic inhibition improves insulin sensitivity in obese mice[46]. 351 
The same authors demonstrated that galectin-3 interferes with insulin signaling by directly binding 352 
to the insulin receptor. 353 
 354 
Myocardial contractile and prohypertrophic biomarkers 355 
Troponins are multiprotein complexes constituted by Troponin I (TnI), C (TnC) and T (TnT) that 356 
regulate calcium-mediated interaction between actin and myosin, thus being directly related to 357 
myocardial contractility. They are released into the circulation from the myocardium during 358 
inflammatory processes and in experimental models of diabetes, particularly in those animals also 359 
presenting heart failure[3, 75], suggesting that they could be useful biomarkers for DCM. TnI and 360 
TnT isoforms are currently used as necrosis markers in clinical practice, since their serum levels 361 
may be predictive for cardiovascular death in patients with myocardial infarction and heart 362 
failure[76]. 363 
In addition, mitochondrial calcium uptake 1 (MICU1), a key regulator of mitochondrial Ca2+ 364 
uptake, is downregulated in the heart during diabetes[77]. This contributes to myocardial 365 
mitochondria-dependent intrinsic apoptosis and the progression of DCM. Of note, MICU1 366 
downregulation caused by hyperglycemia and hyperlipidemia in cardiomyocytes is due to the 367 
inhibition of Sp1, which is diminished in several tissues from diabetic patients[77]. Importantly, 368 
its overexpression in the heart partially prevents the development of DCM by activating the 369 
antioxidant system and reducing myocardial fibrosis and subsequent cardiac hypertrophy[77], thus 370 
pointing to MICU1 activation as a novel therapeutic target in DCM. 371 
Non-physiological hypertrophy is characterized by cardiomyocyte enlargement, increased protein 372 
synthesis and reactivation of fetal gene expression, including -MHC and the natriuretic peptides 373 
A and B (ANP and BNP). These neurohormones are produced and secreted by cardiac cells during 374 
heart failure to counteract the onset of volume and pressure overload via their vasodilator and 375 
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natriuretic effects[78]. Not surprisingly, plasma ANP and BNP, as well as the biologically inactive 376 
precursor N-terminal fragment of BNP (NTproBNP), are currently utilized as biomarkers for heart 377 
failure and myocardial infarction[37, 45], and could also be valuable in the diagnosis or prevention 378 
of DCM. In fact, raised plasma BNP levels are positively correlated with insulin resistance in 379 
prediabetic subjects[79], and display a good predictive capacity for left ventricular dysfunction 380 
and heart failure in DCM[37, 75]. However, the specific role, if any, of natriuretic peptides in 381 
DCM onset and development remains controversial. Some studies report reduced plasma levels 382 
and deficient ANP and BNP signaling in obese, insulin-resistant and diabetic subjects[80], but the 383 
opposite has also been described[81]. This apparent contradiction could be explained by the 384 
proposed biphasic association of BNP with DM2, in which the diabetes risk would decrease when 385 
BNP concentrations lie within the so-called “physiological range”, but would rise when BNP 386 
levels increase due to pathophysiological conditions (i.e. myocardial infarction and heart failure).  387 
 388 
Miscellaneous biomarkers: miRNAs and fibroblast growth factors (FGFs) 389 
Numerous miRNAs are differentially expressed in cardiac tissue of a streptozotocin-induced 390 
mouse model of DM1; some of them exert their deleterious effects through targeting genes 391 
associated with cardiac hypertrophy and fibrosis[82]. Among those regulating cardiac fibrosis 392 
miR-21, miR-29b, miR-142-3p and miR-700[83], which act through pathways requiring p38 393 
MAPK activation, modulation of TGF activity and synthesis of type I collagen, are of particular 394 
interest. Other interesting miRNAs include miR-133a, miR-150, and miR-373, which regulate 395 
cardiac hypertrophy and fibrosis by modulating the activity of the myocyte enhancer factor 2C 396 
transcription factor[82-85]. In a similar way, miR-208a is a prohypertrophic cardiac-specific 397 
miRNA that acts through the repression of myostatin and GATA4[83]. 398 
Hyperglycemia induces the expression of miR-1 and miR-34a in cardiomyoblasts, which promote 399 
apoptosis[82]. miR-1 also negatively regulates calcium signalling during cardiac contractility by 400 
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targeting Junctin, a component of the ryanodine receptor Ca2+ release channel complex[86]. In a 401 
DM2 rat model, miR-320 promotes apoptosis by targeting genes such as vascular endothelial 402 
growth factor and fibroblast growth factors (FGF)[82], while key regulators of apoptosis, 403 
including p53 and p21, are induced by miR-30c and miR-181a during DCM[87]. Also, 404 
overexpression of miR-141 in streptozotocin-induced diabetic mice disrupts mitochondrial energy 405 
production by inhibiting the expression of an inner mitochondrial phosphate transporter, which 406 
eventually results in cell death[82]. On the other hand, miR-30d, which is enhanced in a DM1 407 
animal model, promotes cardiomyocyte proinflammatory-induced apoptosis through the 408 
activation of caspase-1 and secretion of proinflammatory cytokines[88]. The same research group 409 
suggested an opposite role for miR-9[89]. More recently, Deng et al. reported a significant 410 
reduction in the expression levels of circulating miR-24 in blood of DM2 patients with coronary 411 
heart disease[90]. Since miR-24 directly targets YKL40, this results in an interesting and 412 
potentially beneficial appealing increase in YKL40 expression. Finally, studies investigating the 413 
role of miRNAs in the regulation of autophagy and mitophagy during DCM have revealed an 414 
important role for miR30a, miR-133a, miR-212 and miR-221[83]. 415 
MicroRNAs also stand out due to their extensive effects on the control of glucose uptake and 416 
cardiac metabolism in the diabetic heart. For instance, miR-133a reduces the levels of GLUT4 417 
expression[91], whereas miR-223 induces GLUT4 protein expression[92]. Other examples 418 
include the miR-199a/miR-214 cluster, which inhibits PPAR/ to impair mitochondrial fatty acid 419 
oxidation[93], and miR-451, which exacerbates lipotoxicity and cardiac hypertrophy in a mouse 420 
model of DM2 through the suppression of AMP-activated protein kinase (AMPK) activity, a 421 
master regulator of cardiac glucose and FA metabolism[94].  422 
In summary, the expression of numerous miRNAs is dysregulated in the heart and even modified 423 
in the plasma of diabetic individuals. For this reason, miRNAs have been proposed as potential 424 
serum biomarkers for the prognosis and diagnosis of patients with DCM. As an example, a recently 425 
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published study indicated that plasma miR-19b-3p and miR-181b-5p levels could be suitable 426 
biomarkers of DCM in asymptomatic diabetic patients[95]. Moreover, since several of these 427 
miRNAs are causatively associated with the disease, the development of anti-miRNAs 428 
(antagomiRs) and miRNA mimics to target them could be a potential approach for future 429 
therapeutic intervention. For instance, intravenous administration of antagomiRs targeting miR-430 
132 and miR-133 protects the heart against cardiac fibrosis, hypertrophy and heart failure[96, 97], 431 
and cardiomyocyte-specific miR-451 knockout mice are partially resistant to diabetes-induced 432 
cardiac hypertrophy and contractile dysfunction[94]. 433 
With regard to fibroblast growth factors (FGF), the most notable in the heart are FGF1, FGF2 and, 434 
above all, FGF21 and FGF23. FGF1 displays high expression in the heart and is transcriptionally 435 
induced by PPAR, PPAR/ and PPAR agonists[98]. FGF2, which is expressed in both 436 
cardiomyocytes and fibroblasts, causes extracellular matrix deposition and apoptosis, thus leading 437 
to pathological cardiac hypertrophy[98]. FGF21 and FGF23 function as local signaling molecules 438 
in metabolism through activation of FGF receptors, using -Klotho or -Klotho as a cofactor. 439 
The liver is the main site of expression and release of FGF21 into the blood, although it is also 440 
produced by cardiomyocytes, where it acts in an autocrine manner[99]. In the heart, FGF21 is 441 
under the transcriptional control of the sirtuin 1-PPAR pathway[99]. FGF21 displays powerful 442 
antidiabetic effects due to its broad systemic metabolic actions, which include the improvement of 443 
glucose homeostasis and insulin sensitivity[100]. However, a paradoxically abnormal elevation of 444 
serum FGF21 levels is observed during obesity and, especially, insulin resistance[100]. In 445 
response to prohypertrophic stimuli, FGF21 knockout mice exhibit enhanced cardiac hypertrophy 446 
and inflammation compared to wild-type controls, in addition to greater repression of FA 447 
oxidation[99]. Treatment with exogenous FGF21 reverses all these changes. Likewise, a more 448 
recent study highlighted the antioxidative role of FGF21 in the heart[101]. As a result, FGF21 449 
reduces ROS production and protects the heart against inflammatory or prohypertrophic 450 
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stimuli[101]. Interestingly, ablation of FGF21 in a mouse model of DM1 exacerbates DCM 451 
through a FAT/CD36-mediated increase in cardiac lipid uptake and accumulation, which in turn 452 
impairs cardiac lipid and glucose utilization and mitochondrial function[102]. This exacerbates 453 
cardiac oxidative stress and provokes inflammation and cardiomyocyte apoptosis. Conversely, 454 
FGF21 overexpression improves hyperglycemia-induced DCM via attenuation of cardiac 455 
hypertrophy, fibrosis, oxidative stress and inflammation, in a process requiring both -klotho and 456 
AMPK[102]. 457 
Less is known about FGF23. It regulates phosphorus homeostasis in the kidney and parathyroid 458 
glands, and some studies have unveiled a causal role for FGF23 in the pathogenesis of left 459 
ventricular hypertrophy via activation of phospholipase C and calcineurin-NFAT (nuclear factor 460 
in activated T cells) signaling pathways[103]. In the diabetic population, plasma levels of FGF23 461 
are increased[104], and some studies point to its suitability as an atherosclerosis biomarker in these 462 
patients[105]. 463 
 464 
Concluding remarks  465 
The relatively slow evolution of DCM and its associated high morbidity and mortality make the 466 
validation of new, reliable and specific biomarkers that would allow more efficient and early 467 
diagnosis of utmost importance. Several standardized biomarkers have been validated by the FDA 468 
for the diagnosis and risk assessment of various cardiac diseases to date, but they are not able to 469 
distinguish patients with DCM, particularly in the early stages, i.e. when still asymptomatic but 470 
after dysregulation in cardiac metabolism, inflammation and fibrosis has already begun. Moreover, 471 
assessment of DCM is puzzling in clinical practice owing to the atypical and diverse presentation 472 
of signs and symptoms. 473 
The pathophysiology of DCM has several interconnected backgrounds, including metabolic 474 
dysregulation, low-grade inflammation, oxidative stress, myocardial fibrosis and cardiomyocyte 475 
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apoptosis, which, overall, contribute to the progression and fatal outcomes of the disease. 476 
Therefore, the best approach to detect DCM prior to the appearance of clinical symptoms and 477 
irreversible complications will likely involve combining echocardiographic imaging techniques to 478 
evaluate changes in cardiac structure and function, and the quantification of a panel of minimally-479 
invasive biomarkers covering the main diabetes-induced alterations in the heart (see Outstanding 480 
Questions). This multi-biomarker approach would be quite time-consuming and may incur a 481 
higher cost than traditional biomarkers, but would improve the diagnosis and prognosis of the 482 
disease, and would bypass the problems observed when relying on single biomarkers.  483 
In this review we highlight several candidates that fulfil the requirements for becoming biomarkers 484 
with the potential to detect or prevent DCM, or even to treat it once established. Among them, 485 
FABP3, activin A, CT-1, YKL40, galectin-3, IGFBP-7, FGF21 and several miRNAs stand out 486 
because they can be measured by minimally-invasive methods, they integrate several 487 
pathophysiological pathways and, last but not least, they are potentially capable of distinguishing 488 
patients with DCM also in the early stages. Of course, further preclinical studies are required to 489 
unequivocally elucidate the role of these biomarkers in the development and progression of DCM 490 
and to fine-tune their detection methods. Afterwards, additional clinical data will be necessary to 491 
explain some of the conflicting results observed in clinical trials and to establish key values or 492 
ranges of these biomarkers according to the type and severity of diabetes, and the characteristics 493 
of the patients. 494 
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Advanced glycation end-products: proteins or lipids that are glycated and oxidized as a 745 
consequence of persistent exposure to high concentrations of reducing sugars (e.g. glucose), and 746 
that are causatively associated with complications of diabetes. 747 
Apoptosis: genetically programmed cell death that is characterized by the fragmentation of 748 
nuclear DNA, and which aims to eliminate DNA-damaged, superfluous or unwanted cells. 749 
Autophagy: homeostatic process that involves cell degradation of unnecessary or dysfunctional 750 
cytoplasmic components ranging from protein aggregates to whole organelles through the action 751 
of lysosomes. 752 
Cardiac hypertrophy: abnormal thickening of the heart muscle that results from cardiomyocyte 753 
enlargement and changes in the extracellular matrix. 754 
Cardiac output: volume of blood being pumped by the heart per unit time. 755 
Cardiac remodeling: is the result of an imbalance between pro- and antifibrotic factors that 756 
promotes extracellular matrix protein deposition. The resultant cardiac fibrosis impairs 757 
cardiomyocyte contractility and, ultimately, leads to cardiac stiffness and heart failure. 758 
Cardiac steatosis: excessive accumulation of triglycerides in cardiomyocytes. 759 
Cytokines and chemokines: extracellular mediators that participate in the regulation of acute and 760 
chronic inflammation. 761 
Dilated cardiomyopathy: condition in which the heart becomes enlarged and cannot pump blood 762 
efficiently. 763 
Diastolic dysfunction: impaired ventricular relaxation and filling resulting in a higher end-764 
diastolic pressure for a given end-diastolic volume. 765 
Endoplasmic reticulum (ER) stress: ER is the subcellular organelle responsible for protein 766 
folding and maturation. Any perturbation that hinders these processes will give rise to the 767 
accumulation of unfolded or misfolded proteins, which leads to the activation of the unfolded 768 
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protein response (UPR) by the ER. The purpose of the UPR is to promote cell survival by 769 
mitigating the adverse effects of ER stress, and this is achieved by arresting general mRNA 770 
translation, facilitating protein degradation and enhancing the production of molecular chaperones 771 
involved in protein folding. 772 
Fibroblast growth factors (FGF): small signaling proteins (~150–300 amino acids) with diverse 773 
biological functions, mainly in development and metabolism. The family comprises up to 23 774 
members (FGF1-FGF23), which display paracrine, intracrine, and endocrine actions. 775 
Insulin resistance: condition in which the cells of the body do not respond properly to the 776 
hormone insulin. 777 
microRNA: endogenous non-coding small RNA that modulates gene expression by targeting 778 
mRNAs for post-transcriptional repression. 779 
Oxidative stress: refers to elevated intracellular levels of reactive oxygen species (ROS) that 780 
cause damage to lipids, proteins and DNA. It is caused by an imbalance between the production 781 
of free radicals and the ability of the body to counteract or detoxify their harmful effects by 782 
antioxidants. 783 
Peroxisome proliferator-activated receptors (PPAR): subfamily of the nuclear receptor 784 
superfamily that regulates transcriptional gene expression and plays essential roles in the 785 
regulation of cellular differentiation, development and metabolism. It comprises three isotypes: 786 









Box 1 794 
Clinical features and diagnostic methods of diabetic cardiomyopathy 795 
The diabetic heart is mostly characterized by concentric left ventricular hypertrophy, dilated 796 
cardiomyopathy and extracellular fibrosis. Cardiac remodeling during diabetic cardiomyopathy 797 
(DCM) occurs in different phases. The first area in which obvious pathological changes usually 798 
occur is the myocardial interstitium. This is often followed by perivascular fibrosis and left 799 
ventricular hypertrophy, which result in impaired relaxation and passive filling of the left ventricle 800 
(diastolic dysfunction)[3]. Diastolic dysfunction is habitually the earliest functional abnormality 801 
detected in DCM, and may even be found in asymptomatic diabetic patients and patients with good 802 
glycemic control. Conversely, systolic dysfunction, defined as the inability of the myocardium to 803 
eject an adequate blood volume, is less frequent and typically develops in the later stages of the 804 
disease. 805 
Despite the different techniques available nowadays, there is no gold-standard diagnostic test for 806 
DCM. Indeed, DCM is usually detected through identification of systolic dysfunction at late stages 807 
of the disease, when heart failure is already established. Endomyocardial biopsy sampling and 808 
cardiac catheterization are accurate methods for diagnosing diastolic dysfunction in the early 809 
stages, but because of the high risk they pose, their use has been confined to research settings[37]. 810 
Two-dimensional, and more recently three-dimensional, echocardiography are valuable 811 
inexpensive and non-invasive tools to detect functional and structural cardiac disorders in real 812 
time, including early fibrosis and cardiac hypertrophy[37]. Magnetic resonance imaging displays 813 
greater accuracy and reproducibility than echocardiography, and is valid for measuring left 814 
ventricular mass, myocardial steatosis and diastolic dysfunction, besides providing data about 815 
myocardial fibrosis. Nevertheless, it is currently only used for research purposes due to its 816 
demanding time, cost and expertise requirements. Finally, positron emission tomography scanning 817 
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has been successfully used to detect myocardial metabolic abnormalities in murine models of 818 
DCM and asymptomatic DM2 patients. 819 
 820 
Box 2 821 
Treatment approaches for diabetic cardiomyopathy 822 
There are no formal guidelines regarding the management of diabetic cardiomyopathy (DCM) but, 823 
as a general rule, it includes lifestyle modifications (weight loss, restriction of total energy intake 824 
and regular physical activity), improvement of glycemic control, lipid-lowering drugs, and the 825 
management of heart failure itself.  826 
The PPAR agonists thiazoledinediones (TZD) are hypoglycemic insulin-sensitizing drugs that 827 
improve myocardial glucose metabolism in addition to displaying some beneficial 828 
antiinflammatory and profibrinolytic effects[106]. However, chronic TZD treatment may favor 829 
the occurrence of symptoms that resemble heart failure, and for that reason they are not 830 
recommended in patients suffering this pathology[3]. Likewise, metformin is a first-line 831 
medication for the treatment of DM2 that prevents DCM in experimental models and reduces 832 
morbidity and mortality in overweight patients with heart failure and diabetes, but that was till 833 
recently contraindicated in patients with heart failure because it causes lactic acidosis[3]. Similar 834 
conflicting results have been reported with other classic antidiabetic medicines (sulfonylureas and 835 
insulin)[15]. With regard to newer antidiabetic drugs (glucagon-like peptide-1 mimetic agents and 836 
dipeptidyl peptidase 4 inhibitors)[3, 15], or lipid-lowering drugs (statins)[107], there are some 837 
encouraging data pointing to their cardioprotective effects, but additional clinical trials are 838 
required to determine their efficacy and safety in DCM. 839 
The antihypertensive drugs angiotensin converting enzyme inhibitors, renin inhibitors and 840 
angiotensin II receptor blockers also protect the heart in both human and animal models of 841 
DCM[3]. Similarly, -adrenoreceptor antagonists[108] and calcium channel blockers[109] have 842 
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both shown protective effects against DCM, suggesting their putative suitability in hypertensive 843 
patients with DCM. Finally, antianginal metabolic modulators (trimetazidine, ranolazine) are also 844 
promising drugs for treating DCM in the near future, since they may correct the metabolic 845 
dysregulation occurring during this pathology, at the same time they display beneficial pleiotropic 846 
effects on oxidative stress, lipotoxicity, calcium handling and apoptosis[3]. 847 
 848 
Box 3 849 
Regulation of heart contraction by calcium 850 
Calcium ions are pivotal regulators in the process of excitation-contraction coupling in the heart. 851 
Once the action potential reaches the cardiomyocyte, the cell membrane is depolarized and calcium 852 
enters the cell through voltage-dependent L-type calcium channels in the sarcolemma. This 853 
increased intracellular calcium activates the ryanodine receptors located in the sarcoplasmic 854 
reticulum to trigger the massive release of further calcium ions from this store. Then, cytosolic 855 
calcium will bind to myofilaments in order to begin cardiomyocyte contraction. Removal of 856 
calcium from the cytosol results in the opposite process of cardiomyocyte relaxation, and this is 857 
mostly carried out by pumping calcium back into the sarcoplasmic reticulum by SERCA 858 
(sarcoplasmic/endoplasmic reticulum Ca2+-ATPase), although other processes may intervene 859 
(mitochondrial calcium uniport, PMCA or plasma-membrane Ca2+-ATPase and Na+/Ca2+ 860 









Figure legends 868 
Figure 1. Major pathophysiological mechanisms of diabetic cardiomyopathy. Diabetes 869 
induces an increase in plasma free fatty acids (FA) and glucose levels, which are internalized into 870 
cardiomyocytes by fatty acid translocase (FAT/CD36) and the insulin-induced glucose transporter 871 
4 (GLUT4), respectively. Excess FA stimulates the peroxisome proliferator-activated receptor 872 
(PPAR)/PGC-1 (PPAR coactivator-1) pathway, leading to increased transcription of genes 873 
involved in FA uptake and oxidation (CPT1, carnitine palmitoyl-transferase 1, and FAT/CD36). 874 
Another PPAR-induced gene, the pyruvate dehydrogenase kinase 4 (PDK4), decreases glucose 875 
oxidation by inactivating the pyruvate dehydrogenase complex (PDC). This causes an increase in 876 
fatty acid oxidation, which will lead to mitochondrial dysfunction, the loss of metabolic flexibility 877 
and energy production efficiency (ATP) by the heart, and the generation of reactive oxygen species 878 
(ROS) by the mitochondria. On the other hand, downregulated insulin signaling as a consequence 879 
of insulin resistance prevents GLUT4 translocation from intracellular vesicles towards the 880 
sarcolemma, thus reducing glucose uptake and utilization, and promoting a substrate shift toward 881 
increased mitochondrial FA β-oxidation. Despite the higher FA oxidation rate, myocardial lipid 882 
accumulation (cardiac steatosis) occurs, and the subsequent formation of toxic lipid intermediates 883 
(ceramides and diacylglycerol, DAG) contributes to the development of heart failure. These 884 
intermediates activate the proinflammatory NF-κB and activator protein-1 (AP-1) transcription 885 
factors and favor the onset of endoplasmic reticulum (ER) stress and mitochondrial dysfunction. 886 
On the other hand, hyperglycemia also induces the formation of advanced glycation end-products 887 
(AGE) and ROS within the cardiomyocytes, which trigger NF-κB activation, hence inducing 888 
inflammation (cytokines and chemokines) and interstitial fibrosis (MMP, matrix 889 
metalloproteinase; TGF, transforming growth factor ). ROS accumulation also hastens 890 
apoptosis and brings on ER stress in cardiomyocytes. As a consequence, calcium handling is 891 




Figure 2. Emerging metabolism-related components in diabetic cardiomyopathy. In the 894 
phosphocreatine (PCr)/creatine (Cr) “shuttle” system, phosphate is transferred from the ATP 895 
formed in the mitochondria to Cr via mitochondrial creatine kinase (mtCK), generating PCr. Then, 896 
PCr diffuses into the cytoplasm, where the muscle-type creatine kinase (mmCK) forms Cr and 897 
ATP, the latter participating in myofibril (cardiomyocyte) contraction. The fatty acid binding 898 
protein 3 (FABP3) is a cardiac-specific PPAR-target protein induced during diabetes that 899 
transports long-chain fatty acids (FA) to the mitochondria for their subsequent oxidation, and also 900 
to the nucleus to activate PPAR-dependent gene expression. FABP3 is involved in cardiac 901 
steatosis and mitochondrial dysfunction by excess FA delivery, and also has an antiapoptotic role. 902 
The formation of toxic lipid intermediates (ceramides and diacylglycerol, DAG) induces 903 
endoplasmic reticulum (ER) stress, thus altering membrane synthesis and reducing calcium release 904 
(i.e. cardiomyocyte contraction). TRIM72 (tripartite motif containing 72) impairs insulin signaling 905 
because it drives ubiquitin-dependent degradation of insulin receptor (IR) and insulin receptor 906 
substrate 1 (IRS1), thus increasing the reliance of the heart on FA as an energy source and PPAR 907 
activity. TRIM72 also plays an important role in cardiac fibrosis through the modulation of the 908 
transforming growth factor (TGF). In a similar way, TP53INP2 (tumour protein p53 inducible 909 
nuclear protein 2), the expression of which is induced by PPAR, regulates the expression of 910 
important glycolytic enzymes involved in glucose uptake and glycogen storage in cardiomyocytes. 911 
TP53INP2 is also a key regulator of autophagy and protein degradation, thus hindering the 912 
expression of hypertrophic genes, particularly in the context of hyperglycaemia. 913 
 914 
Figure 3. Emerging molecules involved in inflammation and fibrosis. Cardiotrophin-1 (CT-1) 915 
promotes cardiac fibrosis and remodeling and inhibits apoptosis by activating the JAK/STAT3 916 
(janus kinase/signal transducer and activator of transcription 3) pathway. Galectin-3 (Gal-3), 917 
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which is locally secreted by macrophages and fibroblasts, promotes inflammation and fibrosis by 918 
enhancing myofibroblast proliferation, accumulation of extracellular matrix and macrophage 919 
infiltration, via stimulation of the TGFβ (transforming growth factor ) signaling pathway. Gal-3 920 
also interferes with insulin signaling by binding to the insulin receptor (IR). YKL-40 attenuates 921 
NF-B-dependent inflammation (cytokines and chemokines), apoptosis, tissue remodeling and 922 
fibrosis (MMPs, collagens, TGF). Likewise, through the inhibition of NF-B, GDF15 (growth 923 
differentiation factor 15) suppresses the synthesis and secretion of proinflammatory cytokines 924 
(TNF-, IL6). HMGB1 (high-mobility group box 1), the expression of which is induced in 925 
cardiomyocytes and cardiac fibroblasts by hyperglycemia, and may be released to the myocardial 926 
interstitium, boosts fibrosis and inflammation through the activation of MAPKs (ERK1/2 and 927 
JNK) and NF-B. Its effects rely on binding to the receptor for advanced glycation end products 928 
(RAGE) and toll-like receptors (not shown). HMGB1 also displays negative inotropic effects. 929 
Downregulation of MICU1 (mitochondrial calcium uptake 1) in the heart during diabetes 930 
contributes to myocardial mitochondria-dependent intrinsic apoptosis and fibrosis, and also favors 931 
oxidative stress. Finally, insulin-like growth factor binding protein-7 (IGFBP-7) increases 932 

















































































































































































Emerging actors in diabetic cardiomyopathy: heartbreaker biomarkers or 1 
therapeutic targets? 2 
 3 
Xavier Palomer, Javier Pizarro-Delgado, Manuel Vázquez-Carrera 4 
 5 
Outstanding Questions 6 
Will it be possible in the near future to detect or prevent diabetic cardiomyopathy in the early 7 
stages, or even to treat it once established? 8 
 9 
Is the combination of imaging techniques with the quantification of a panel of biomarkers the best 10 
approach to detect diabetic cardiomyopathy? 11 
 12 
Will it be possible to develop novel biomarkers with potential to discriminate diabetic 13 
cardiomyopathy from other cardiac diseases? Will it be the combination of biomarkers that 14 
integrate inflammation, oxidative stress, fibrosis and metabolic dysregulation useful to selectively 15 
discriminate diabetic cardiomyopathy? 16 
 17 
Will candidate biomarkers belonging to the newly discovered molecular pathways provide new 18 
tools to improve the diagnosis of diabetic cardiomyopathy? Will these biomarkers also be useful 19 
as therapeutic strategies to treat diabetic cardiomyopathy? Are non-coding RNAs appropriate as 20 
novel biomarkers with potential to detect or prevent diabetic cardiomyopathy, or even to treat it 21 
once established? 22 
 23 
Is the quantification of a panel of biomarkers (the multi-biomarker approach) covering the main 24 




dysregulation) a suitable, reliable and feasible method to improve diagnosis and prognosis of the 26 
disease? Which is the best approach to develop, optimize and validate this multi-biomarker panel? 27 
